Reclast, Zoledronic Acid, Zometa, Aclasta (zoledronic acid) is a small molecule pharmaceutical. Zoledronic acid was first approved as Reclast on 2001-03-20. It is used to treat bone neoplasms, extramammary paget disease, hypercalcemia, and multiple myeloma in the USA. It has been approved in Europe to treat bone fractures, hypercalcemia, neoplasms, osteitis deformans, and osteoporosis amongst others. The pharmaceutical is active against farnesyl pyrophosphate synthase. In addition, it is known to target Farnesyl pyrophosphate synthase. Reclast's patents are valid until 2028-02-05 (FDA).
|Trade Name||Aclasta, Zometa|
|Common Name||Zoledronic acid|
|Indication||bone fractures, bone neoplasms, extramammary paget disease, hypercalcemia, multiple myeloma, neoplasms, osteitis deformans, osteoporosis, postmenopausal osteoporosis|
|Drug Class||Calcium metabolism regulators|